|
gptkbp:instanceOf
|
antiviral drug
prodrug
|
|
gptkbp:administeredBy
|
oral route
|
|
gptkbp:approvedBy
|
gptkb:FDA
2015
|
|
gptkbp:ATCCode
|
J05AF13
|
|
gptkbp:bioavailability
|
unknown (oral, but higher intracellular levels than tenofovir disoproxil fumarate)
|
|
gptkbp:CASNumber
|
379270-37-8
|
|
gptkbp:category
|
antiretroviral therapy
antiviral
|
|
gptkbp:chemicalFormula
|
C21H29O5N6P
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
nucleotide reverse transcriptase inhibitor
|
|
gptkbp:eliminationHalfLife
|
0.51 hours (plasma)
150–180 hours (intracellular)
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tenofovir alafenamide
|
|
gptkbp:IUPACName
|
isopropyl (2S)-2-[[[(S)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy-methyl-phenoxyphosphoryl]amino]propanoate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Vemlidy
gptkb:Genvoya
gptkb:Descovy
gptkb:Biktarvy
gptkb:Odefsey
|
|
gptkbp:mechanismOfAction
|
inhibits HIV reverse transcriptase
inhibits hepatitis B virus polymerase
|
|
gptkbp:metabolism
|
gptkb:carboxylesterase_1
|
|
gptkbp:molecularWeight
|
476.46 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prodrugOf
|
tenofovir
|
|
gptkbp:proteinBinding
|
80%
|
|
gptkbp:PubChem_CID
|
64739
CHEMBL2105758
71741
|
|
gptkbp:relatedTo
|
gptkb:tenofovir_disoproxil_fumarate
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
fatigue
headache
renal impairment
decreased bone mineral density
|
|
gptkbp:UNII
|
G7R826L9TV
|
|
gptkbp:usedFor
|
HIV infection
chronic hepatitis B
|
|
gptkbp:bfsParent
|
gptkb:Nucleoside_Reverse_Transcriptase_Inhibitors
gptkb:Gilead_Sciences,_Inc.
gptkb:Biktarvy
|
|
gptkbp:bfsLayer
|
6
|